A PDL1-Vδ2 bispecific T cell engager combines tumor targeting with immune checkpoint inhibition and modulation of the tumor immune microenvironment

Publication

This study describes a PD-L1-directed bispecific Vδ2 T cell engager designed to combine tumor-cell targeting with immune checkpoint biology.